暂无标题

doi:10.12209/CAIM202211040001

您当前的位置：

首页 >

文章列表页 >

暂无标题

更新时间：2022-11-23

- 暂无标题
- Clinical Archives of Integrative Medicine (2022)
- 作者机构：
  
  北京中医药大学深圳医院（龙岗），深圳， 518172
- 作者简介：
- 基金信息：
- DOI：10.12209/CAIM202211040001
  CLC：
- Published Online：23 November 2022，
  
  Received：04 November 2022，
扫描看全文
[DB/OL].Clinical Archives of Integrative Medicine (2022)
DOI：

[DB/OL].Clinical Archives of Integrative Medicine (2022) DOI： 10.12209/CAIM202211040001.

摘要

分子靶向药所导致的药物性皮疹虽不威胁到生命，但给患者造成了身体上的痛苦和莫大的精神负担，有些患者甚至因此而放弃仑伐替尼的治疗。现代医学对于仑伐替尼所致药疹的治疗在健康指导的基础上主要是通过局部使用短效激素类如氢化可的松软膏或抗生素类软膏如红霉素软膏等，但效果不太理想，因此寻找一种效果明显且毒副作用小的治疗方法就显得尤为重要。本案例总结1例肝癌患者使用靶向药物仑伐替尼致药物性皮疹的中医护理及护理体会。包括严密观察患者生命体征和病情变化，对症运用中医外治法治疗患者皮疹，缓解患者皮肤溃烂，增加皮肤自身的抵抗力，使患者在口服仑伐替尼的同时既能减缓肿瘤进程，又可充分减轻皮疹带来的不适感，从而获得最好的治疗效果。

Abstract

Although the drug-induced rash caused by molecular targeted drugs is not life-threatening， it has caused physical pain and great mental burden to patients， and some patients even give up lenvatinib treatment because of this. Modern medicine for the treatment of drug eruptions caused by lenvatinib on the basis of health guidance is mainly through the topical use of short-acting hormones such as hydrocortisone ointment or antibiotic ointment such as erythromycin ointment， but the effect is not ideal， so it is particularly important to find a treatment with obvious effect and small toxic side effects. This case review of the TCM nursing and nursing experience of a patient with liver cancer using the targeted drug lenvatinib to cause drug-induced rash. Including closely observing the patient's vital signs and disease changes， symptomatically using TCM external treatment to treat the patient's rash， alleviating the patient's skin ulceration， increasing the skin's own resistance， so that the patient can not only slow down the tumor process while taking lenvatinib， but also fully reduce the discomfort caused by the rash， so as to obtain the best treatment effect.

关键词

皮肤护理靶向治疗药物性皮疹中医外治法

Keywords

skin caretargeted treatmentdrug rashChinese medicine

references

FERLAY J， SOERJOMATARAM I， DIKSHIT R， et al. Cancer incidence and mortality worldwide： sources， methods and major patterns in GLOBOCAN 2012［J］. Int J Cancer， 2015， 136（5）： E359-E386.

MCGLYNN K A， PETRICK J L， LONDON W T. Global epidemiology of hepatocellular carcinoma： an emphasis on demographic and regional variability［J］. Clin Liver Dis， 2015， 19（2）： 223-238.

魏建莹，孙巍，刘晓民，等. 肝细胞癌的靶向及免疫治疗进展［J］. 临床肝胆病杂志， 2020， 36（10）： 2320-2324.

WEI J Y， SUN W， LIU X M， et al. Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma［J］. J Clin Hepatol， 2020， 36（10）： 2320-2324.（in Chinese）

于悦，时静，刘玉国. 乐伐替尼治疗恶性肿瘤的研究进展［J］. 中国医院药学杂志， 2018， 38（9）： 1005-1009.

YU Y， SHI J， LIU Y G. Current status and development of lenvatinib in the treatment of malignant tumors［J］. Chin J Hosp Pharm， 2018， 38（9）： 1005-1009.（in Chinese）

秦蜀，贺凯，李波，等. 乐伐替尼调控VEGFR/NF-κB/R1P2信号治疗原发性肝细胞性肝癌的机制研究［J］. 东南大学学报（医学版）， 2019， 38（1）： 84-88.

QIN S， HE K， LI B， et al. Mechanism of levitinib regulating VEGFR/NF-κB/R1P2 signaling in treatment of primary liver cancer［J］. J Southeast Univ Med Sci Ed， 2019， 38（1）： 84-88.（in Chinese）

王慧，顾红燕，彭德明，等. 仑伐替尼致不良反应文献分析［J］. 中国新药杂志， 2020， 29（14）： 1675-1680.

WANG H， GU H Y， PENG D M， et al. Literature analysis of adverse drug reactions induced by lenvatinib［J］. Chin J New Drugs， 2020， 29（14）： 1675-1680.（in Chinese）

胡梦奕，陈培丰. 中医药治疗EGFR抑制剂所致皮疹研究进展［J］. 江西中医药大学学报， 2016， 28（3）： 122-124.

HU M Y， CHEN P F. Research progress in therapy of EGFRI- associated rash by traditional Chinese medicine［J］. J Jiangxi Univ Tradit Chin Med， 2016， 28（3）： 122-124.（in Chinese）

冯丽芳，郝丽萍，王龙源，等. 药源性皮疹与药物代谢的相关性研究［J］. 中国药物经济学， 2020， 15（7）： 124-128.

FENG L F， HAO L P， WANG L Y， et al. Advances in the correlation between cutaneous drug eruptions and drug metabolism［J］. China J Pharm Econ， 2020， 15（7）： 124-128.（in Chinese）

刘洁，张洪亮. 表皮生长因子受体抑制剂（EGFRIs）引起的药物性皮疹的中药治疗现状［J］. 新疆中医药， 2018， 36（5）： 117-118.

LIU J， ZHANG H L. Current situation of traditional Chinese medicine treatment of drug-induced skin rash caused by epidermal growth factor receptor inhibitor （EGFRIs）［J］. Xinjiang J Tradit Chin Med， 2018， 36（5）： 117-118.（in Chinese）

曹静文，翟笑枫. 中医药改善靶向药不良反应的研究进展［J］. 中国中医药现代远程教育， 2021， 19（1）： 201-203.

CAO J W， ZHAI X F. Research progress of traditional Chinese medicine in improving the adverse reactions of targeted drugs［J］. Chin Med Mod Distance Educ China， 2021， 19（1）： 201-203.（in Chinese）

于玲，侯继秋，王冬雪，等. 新药乐伐替尼用于治疗肝癌患者的药学监护一例［J］. 实用药物与临床， 2019， 22（7）： 754-757.

YU L， HOU J Q， WANG D X， et al. Pharmaceutical care of lenvatinib in the treatment of one case of hepatocellular carcinoma［J］. Pract Pharm Clin Remedies， 2019， 22（7）： 754-757.（in Chinese）

更多指标>

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Nursing Experience of a Patient with Hand and Foot Syndrome Treated by Fumigation and Washing Technique of Traditional Chinese Medicine

Evidence-based nursing for elderly patients with incontinence dermatitis： A case report

A case report of medical adhesive-related skin injury and related evidence-based nursing practice

Nursing of a case of bullous pemphigoid complicated with hydrocephalus and respiratory disorders

Related Author

No data

Related Institution

Beijing Nniversity Of Chinese Medicine Third Affiliated HospitalAcupuncture And Moxibustion Minimally Invasive Oncology Department

Department of Geriatrics， Beijing University of Chinese Medicine Third Affiliated Hospital

School of Nursing Beijing University of Chinese Medicine

Department of Nephrology， Dongfang Hospital Beijing University of Chinese Medicine

Department of Nursing， Dongfang Hospital Beijing University of Chinese Medicine

⁰

暂无标题

DOI：10.12209/CAIM202211040001

摘要

Abstract

关键词

Keywords

references